Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].

Liang J, Li QF, Yao RY, Lü HY, Jiang J, Sun YY, Song SA, Jiang T.

Zhonghua Zhong Liu Za Zhi. 2010 Jul;32(7):515-9. Chinese.

PMID:
21029695
2.

Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Huang ZH, Hua D, Du X.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1001-7. doi: 10.1007/s00280-009-0956-2. Epub 2009 Feb 27.

PMID:
19247656
3.

Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.

Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, Roh MS, Kim DC, Park KJ, Choi HJ, Kim HJ.

Am J Clin Oncol. 2009 Feb;32(1):38-43. doi: 10.1097/COC.0b013e31817be58e.

PMID:
19194123
4.

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.

Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4.

PMID:
19960344
5.
6.

Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.

Liu B, Wei J, Zou Z, Qian X, Nakamura T, Zhang W, Ding Y, Feng J, Yu L.

Eur J Hum Genet. 2007 Oct;15(10):1049-53. Epub 2007 Jun 27.

7.
8.

[Predictive values of platinum-related gene polymorphisms in gastric cancer patients on oxaliplatin-based adjuvant chemotherapy].

Liu YP, Ling Y, Zhang YP, Liu BR.

Zhonghua Yi Xue Za Zhi. 2011 Jan 25;91(4):256-9. Chinese.

PMID:
21418871
9.
10.

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.

Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, Silva R, Mattioli R, Floriani I, Magnani M.

J Clin Oncol. 2007 Apr 1;25(10):1247-54. Erratum in: J Clin Oncol. 2009 Jul 1;27(19):3262.

PMID:
17401013
11.

Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes.

Inada M, Sato M, Morita S, Kitagawa K, Kawada K, Mitsuma A, Sawaki M, Fujita K, Ando Y.

Int J Clin Pharmacol Ther. 2010 Nov;48(11):729-34.

PMID:
20979931
12.

Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.

Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD.

Mol Med Rep. 2013 Jun;7(6):1904-11. doi: 10.3892/mmr.2013.1435. Epub 2013 Apr 22.

PMID:
23604281
13.

Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.

Cho YB, Chung HJ, Lee WY, Choi SH, Kim HC, Yun SH, Chun HK.

Anticancer Res. 2011 Nov;31(11):3843-9.

PMID:
22110208
14.

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

Viguier J, Boige V, Miquel C, Pocard M, Giraudeau B, Sabourin JC, Ducreux M, Sarasin A, Praz F.

Clin Cancer Res. 2005 Sep 1;11(17):6212-7.

15.

Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.

Li QF, Yao RY, Liu KW, Lv HY, Jiang T, Liang J.

J Korean Med Sci. 2010 Jun;25(6):846-52. doi: 10.3346/jkms.2010.25.6.846. Epub 2010 May 24.

16.

High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.

Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Herndon JE 2nd, Danenberg PV, Harpole DH Jr.

Clin Cancer Res. 2005 Mar 15;11(6):2215-21.

17.

Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.

Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.

Cancer Chemother Pharmacol. 2011 Oct;68(4):935-44. doi: 10.1007/s00280-011-1558-3. Epub 2011 Feb 5.

PMID:
21298384
18.

Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.

Liu R, Zhao X, Liu X, Chen Z, Qiu L, Geng R, Guo W, He G, Yin J, Li J, Zhu X.

Tumour Biol. 2016 Feb;37(2):1753-62. doi: 10.1007/s13277-015-3935-8. Epub 2015 Aug 28.

PMID:
26314858
19.

Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.

Páez D, Salazar J, Paré L, Pertriz L, Targarona E, del Rio E, Barnadas A, Marcuello E, Baiget M.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1319-27. doi: 10.1016/j.ijrobp.2011.01.025. Epub 2011 May 11.

PMID:
21570215
20.

Supplemental Content

Support Center